{"id":5615,"date":"2023-09-04T03:12:45","date_gmt":"2023-09-04T03:12:45","guid":{"rendered":"https:\/\/cm.vastapps.dev\/tcia-collection\/pdmr-bl0293-f563\/"},"modified":"2023-09-13T11:59:55","modified_gmt":"2023-09-13T11:59:55","slug":"pdmr-bl0293-f563","status":"publish","type":"tcia_collection","link":"https:\/\/cm.vastapps.dev\/tcia-collection\/pdmr-bl0293-f563\/","title":{"rendered":"PDMR-BL0293-F563"},"featured_media":0,"template":"","citation-tax":[],"cancer_types":["Bladder Cancer"],"citations":[4506,4507,2925],"collection_doi":"10.7937\/tcia.2019.b6u7wmqw","collection_download_info":"Click the Versions tab for more info about data releases.","collection_downloads":[5088],"full_export":"

Summary<\/h2>

<\/p>Pre-clinical animal models of spontaneous metastatic cancer are infrequent; the few that exist\u00a0are resource intensive because determination of the presence of metastatic disease,\u00a0metastatic burden, and response to therapy normally require animal sacrifice and extensive\u00a0pathological examination. We recently identified and characterized a patient derived xenograft\u00a0model with metastatic potential, bladder xenograft BL0293-F563, developed by Jackson\u00a0Laboratories and the University of California at Davis. In this study we performed a detailed\u00a0imaging characterization of this model, which develops spontaneous liver and bone\u00a0metastases. Using non-contrast T2 weighted MRI, hepatic metastases were demonstrated in\u00a0over 70% of animals at 52 days post tumor implantation without resection of the xenograft and\u00a0in 100% of animals at day 52 following resection of the xenograft. T2w turbo spin echo (T2wTSE) sequence was applied in the coronal view with a repetition time (TR) 5333ms, echo time\u00a0(TE) 65ms, with an in-plane pixel of 0.180 \u00d7 0.180 mm2. A Spectral Presaturation with\u00a0Inversion Recovery (SPIR) sequence (Philips Healthcare, Best, The Netherlands) was used to\u00a0suppress the fat component and assist in distinguishing fat from cystic mass and tumor\u00a0tissue. In a group of animals receiving one cycle of effective chemotherapy ([Temozolomide;\u00a0(50 mg\/kg; PO, QDx5)] plus [(veliparib, a poly (ADP-ribose) polymerase inhibitor) (7.75 mg\/kg;\u00a0PO; BIDx7)]), no animals demonstrated metastasis by imaging. The imaging characteristics of\u00a0this model, which is available from the National Cancer Institute Patient-Derived Models\u00a0Repository (https:\/\/pdmr.cancer.gov\/<\/a>), is highly favorable for preclinical research studies of\u00a0metastatic disease when used in conjunction with non-contrast T2 weighted MRI.

<\/p>

Acknowledgements<\/span><\/p>